BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS;  IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-593. [PMID: 19625712 DOI: 10.1056/nejmoa0808010] [Cited by in Crossref: 855] [Cited by in F6Publishing: 294] [Article Influence: 65.8] [Reference Citation Analysis]
Number Citing Articles
1 Martini A, Gallotta A, Pontisso P, Fassina G. Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. World J Hepatol 2015; 7(29): 2913-2919 [PMID: 26689503 DOI: 10.4254/wjh.v7.i29.2913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 González-Moreno J, Payeras-Cifre A. Hepatitis C virus infection: looking for interferon free regimens. ScientificWorldJournal. 2013;2013:825375. [PMID: 23710151 DOI: 10.1155/2013/825375] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
3 Amorosa VK. New frontiers of HCV therapy in HIV/HCV co-infection. Curr HIV/AIDS Rep 2010;7:117-26. [PMID: 20563864 DOI: 10.1007/s11904-010-0051-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Stättermayer AF, Scherzer T, Beinhardt S, Rutter K, Hofer H, Ferenci P. Review article: genetic factors that modify the outcome of viral hepatitis. Aliment Pharmacol Ther 2014;39:1059-70. [PMID: 24654629 DOI: 10.1111/apt.12717] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
5 Quer J, Buti M, Cubero M, Guardia J, Esteban R, Esteban JI. New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents. Infect Drug Resist 2010;3:133-45. [PMID: 21694902 DOI: 10.2147/IDR.S7136] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
6 Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. PLoS One 2016;11:e0151703. [PMID: 27018988 DOI: 10.1371/journal.pone.0151703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Kulkarni AS, Damha MJ, Schinazi RF, Mo H, Doehle B, Sagan SM, Götte M. A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin. Antimicrob Agents Chemother 2016;60:2018-27. [PMID: 26824949 DOI: 10.1128/AAC.02436-15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Schackman BR. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One 2014;9:e97317. [PMID: 24842841 DOI: 10.1371/journal.pone.0097317] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 9.6] [Reference Citation Analysis]
9 Jia Z, Ding Y, Tian S, Niu J, Jiang J. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis. PLoS One. 2012;7:e45698. [PMID: 23029188 DOI: 10.1371/journal.pone.0045698] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
10 d'Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, Lo Caputo S, Castagna A, Mussini C, Cingolani A, Tavelli A, Shanyinde M, Gori A, Girardi E, Andreoni M, Antinori A, Puoti M; Icona Foundation and HepaIcona Study Group. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One 2017;12:e0177402. [PMID: 28520749 DOI: 10.1371/journal.pone.0177402] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
11 Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA. Racial differences in hepatitis C treatment eligibility. Hepatology. 2011;54:70-78. [PMID: 21488082 DOI: 10.1002/hep.24358] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
12 King H, Soh JE, Thompson WW, Brown JR, Rapposelli K, Vellozzi C. Testing for Hepatitis C Virus Infection Among Adults Aged ≥18 in the United States, 2013-2017. Public Health Rep 2021;:333549211047236. [PMID: 34606398 DOI: 10.1177/00333549211047236] [Reference Citation Analysis]
13 Stasi C, Milani S. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. World J Gastroenterol 2016; 22(4): 1711-1720 [PMID: 26819535 DOI: 10.3748/wjg.v22.i4.1711] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
14 Friedman RM, Contente S. Treatment of hepatitis C infections with interferon: a historical perspective. Hepat Res Treat 2010;2010:323926. [PMID: 21152181 DOI: 10.1155/2010/323926] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
15 Danilau D, Litvinchuk D, Solovey N, Krasko O, Karpov I. Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype. Clin Exp Hepatol 2017;3:16-22. [PMID: 28856285 DOI: 10.5114/ceh.2017.65279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Kwo PY, Badshah MB. Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. Curr Gastroenterol Rep 2015;17:462. [PMID: 26342813 DOI: 10.1007/s11894-015-0462-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Cariani E, Roli L, Missale G, Villa E, Ferrari C, Trenti T. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. Pharmacogenomics J. 2015;Epub ahead of print. [PMID: 25918016 DOI: 10.1038/tpj.2015.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
18 Martin CK, Hostetter JE, Hagan JJ. New opportunities for the management and therapy of hepatitis C in correctional settings. Am J Public Health. 2010;100:13-17. [PMID: 20007626 DOI: 10.2105/ajph.2008.147629] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
19 Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun Y, Yang R, Li H, Zhang H, Gong Z, Zhang L, Zhao L, Dou X, Niu J, You H, Chen Z, Ning Q, Gong G, Wu S, Ji W, Mao Q, Tang H, Li S, Wei S, Sun J, Jiang J, Lu L, Jia J, Zhuang H. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2014;29:545-553. [PMID: 24090188 DOI: 10.1111/jgh.12398] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 10.9] [Reference Citation Analysis]
20 Shouval D. One step forward in understanding the differences in antiviral response to interferon a2a and a2b in chronic hepatitis C patients with advanced fibrosis. J Hepatol 2012;56:303-4. [PMID: 22015961 DOI: 10.1016/j.jhep.2011.10.001] [Reference Citation Analysis]
21 Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulkowski M, McHutchison JG, Goldstein DB. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464:405-408. [PMID: 20173735 DOI: 10.1038/nature08825] [Cited by in Crossref: 348] [Cited by in F6Publishing: 323] [Article Influence: 29.0] [Reference Citation Analysis]
22 Shehab H, Elbaz T, Deraz D, Hafez A, Elattar I. The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C. J Interferon Cytokine Res 2014;34:727-33. [PMID: 24730368 DOI: 10.1089/jir.2013.0127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
23 Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:279-290. [PMID: 22351713 DOI: 10.1059/0003-4819-156-4-201202210-00005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Fukasawa M, Nagase S, Shirasago Y, Iida M, Yamashita M, Endo K, Yagi K, Suzuki T, Wakita T, Hanada K, Kuniyasu H, Kondoh M. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model. J Virol 2015;89:4866-79. [PMID: 25673725 DOI: 10.1128/JVI.03676-14] [Cited by in Crossref: 39] [Cited by in F6Publishing: 17] [Article Influence: 5.6] [Reference Citation Analysis]
25 Walker A, Kaiser R, Bartenschlager R, Timm J. Genotypic resistance testing of HCV - is there a clinical need? GMS Infect Dis 2016;4:Doc05. [PMID: 30671319 DOI: 10.3205/id000023] [Reference Citation Analysis]
26 Lim SG. Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings. World J Gastroenterol 2015; 21(6): 1972-1981 [PMID: 25684966 DOI: 10.3748/wjg.v21.i6.1972] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
27 Nucara S, Caroleo B, Guadagnino V, Perrotti N, Trapasso F. Natural history and clinical response: "it's the virus, stupid, or is it the host?". BMC Infect Dis. 2012;12 Suppl 2:S6. [PMID: 23173731 DOI: 10.1186/1471-2334-12-S2-S6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
28 Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity 2019;50:907-23. [PMID: 30995506 DOI: 10.1016/j.immuni.2019.03.025] [Cited by in Crossref: 267] [Cited by in F6Publishing: 252] [Article Influence: 89.0] [Reference Citation Analysis]
29 Wilder JM, Muir AJ. Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. Ther Adv Chronic Dis. 2015;6:314-327. [PMID: 26568808 DOI: 10.1177/2040622315603642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
30 Poordad F. Big changes are coming in hepatitis C. Curr Gastroenterol Rep 2011;13:72-7. [PMID: 21063814 DOI: 10.1007/s11894-010-0153-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
31 El-Shamy A, Hotta H. Impact of hepatitis C virus heterogeneity on interferon sensitivity: An overview. World J Gastroenterol 2014; 20(24): 7555-7569 [PMID: 24976696 DOI: 10.3748/wjg.v20.i24.7555] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
32 Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57:2164-2170. [PMID: 23280550 DOI: 10.1002/hep.26218] [Cited by in Crossref: 307] [Cited by in F6Publishing: 293] [Article Influence: 34.1] [Reference Citation Analysis]
33 Nishikawa H, Iguchi E, Koshikawa Y, Ako S, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Ishikawa T, Saito S, Kita R, Kimura T, Osaki Y. The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients. BMC Res Notes 2012;5:135. [PMID: 22405406 DOI: 10.1186/1756-0500-5-135] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
34 Krassenburg LAP, Zanjir WR, Georgie F, Stotland E, Janssen HLA, Hansen BE, Feld JJ. Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. Clin Infect Dis 2021;72:780-6. [PMID: 32052014 DOI: 10.1093/cid/ciaa144] [Reference Citation Analysis]
35 Thong VD, Wasitthankasem R, Tangkijvanich P, Vongpunsawad S, Poovorawan Y. Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection. PLoS One 2015;10:e0125400. [PMID: 25938236 DOI: 10.1371/journal.pone.0125400] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
36 Aalaei-Andabili SH, Behnava B, Salimi S, Sharafi H, Alavian SM. Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis. Hepat Mon 2014;14:e15895. [PMID: 24734092 DOI: 10.5812/hepatmon.15895] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
37 Druyts E, Thorlund K, Humphreys S, Lion M, Cooper CL, Mills EJ. Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection. Clin Epidemiol 2013;5:173-83. [PMID: 23843702 DOI: 10.2147/CLEP.S44273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
38 Taha AA, El-Ray A, El-Ghannam M, Mounir B. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol 2010;24:597-602. [PMID: 21037988 DOI: 10.1155/2010/717845] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
39 Cooper C. Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success. Can J Gastroenterol 2010;24:385-90. [PMID: 20559582 DOI: 10.1155/2010/125435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Thorlund K, Druyts E, Mills EJ. SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. Clin Epidemiol. 2014;6:49-58. [PMID: 24474846 DOI: 10.2147/CLEP.S53302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
41 Sims KD, Lemm J, Eley T, Liu M, Berglind A, Sherman D, Lawitz E, Vutikullird AB, Tebas P, Gao M, Pasquinelli C, Grasela DM. Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection. Antimicrob Agents Chemother 2014;58:3496-503. [PMID: 24733462 DOI: 10.1128/AAC.02579-13] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
42 Kim do Y, Ahn SH, Han KH. Emerging therapies for hepatitis C. Gut Liver. 2014;8:471-479. [PMID: 25228970 DOI: 10.5009/gnl14083] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
43 Malnick S, Maor Y, Melzer E, Tal S. Chronic hepatitis C in the aged: much ado about nothing or nothing to do? Drugs Aging 2014;31:339-47. [PMID: 24664397 DOI: 10.1007/s40266-014-0170-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
44 Yasin T, Riley TR, Schreibman IR. Current treatment of choice for chronic hepatitis C infection. Infect Drug Resist. 2011;4:11-18. [PMID: 21694905 DOI: 10.2147/IDR.S4827] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
45 Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, Vinci M, Belli LS, Mantovani LG, Strazzabosco M. Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. J Viral Hepat 2015;22:175-83. [PMID: 25040391 DOI: 10.1111/jvh.12278] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
46 Méndez-Lagares G, Lu D, Chen C, Terrault N, Segal MR, Khalili M, Monto A, Shen H, Manos MM, Lanier LL, Ryan JC, McCune JM, Hartigan-O'Connor DJ. Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. J Immunol 2018;200:1124-32. [PMID: 29263212 DOI: 10.4049/jimmunol.1701364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
47 Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012;26:359-75. [PMID: 22720279 DOI: 10.1155/2012/947676] [Cited by in Crossref: 40] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
48 Jhaveri R, Broder T, Bhattacharya D, Peters MG, Kim AY, Jonas MM. Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now. Clin Infect Dis 2018;67:1493-7. [PMID: 30215670 DOI: 10.1093/cid/ciy586] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
49 da Silva Conde SR, Soares Monteiro JC, Silva Dos Santos BT, Fonseca Filgueiras NK, de Almeida Lins PA, Bonfim Freitas F, da Silva Graça E, Demachki S, Ferreira de Araújo MT, Ishak R, Rosário Vallinoto AC. SNP rs8099917 in gene IL28B might be associated with risk of chronic infection by HCV but not with response to treatment. Biomed Res Int 2014;2014:748606. [PMID: 24678513 DOI: 10.1155/2014/748606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
50 Omata M, Kanda T, Yu M, Yokosuka O, Lim S, Jafri W, Tateishi R, Hamid SS, Chuang W, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao J, Mccaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35. [DOI: 10.1007/s12072-012-9342-y] [Cited by in Crossref: 114] [Cited by in F6Publishing: 128] [Article Influence: 11.4] [Reference Citation Analysis]
51 Kapol N, Lochid-Amnuay S, Teerawattananon Y. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6. BMC Gastroenterol 2016;16:91. [PMID: 27492396 DOI: 10.1186/s12876-016-0506-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
52 Jeng WJ, Lin CY, Chen JY, Huang CW, Huang CH, Sheen IS. None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis. PLoS One 2012;7:e48217. [PMID: 23173032 DOI: 10.1371/journal.pone.0048217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
53 Kuo MT, Hu TH, Lu SN, Hung CH, Wang JH, Chen CH, Chiu YC, Lee CM. Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin therapy for chronic hepatitis C. Dis Markers 2014;2014:462958. [PMID: 25505815 DOI: 10.1155/2014/462958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
54 Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010;4:548-561. [PMID: 21063477 DOI: 10.1007/s12072-010-9193-3] [Cited by in Crossref: 76] [Cited by in F6Publishing: 96] [Article Influence: 6.3] [Reference Citation Analysis]
55 Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:279-290. [PMID: 22351713 DOI: 10.7326/0003-4819-156-4-201202210-00005] [Cited by in Crossref: 142] [Cited by in F6Publishing: 139] [Article Influence: 14.2] [Reference Citation Analysis]
56 Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamuta M, Izumi N, Watanabe S, Tsubota A, Komatsu M, Masaki T, Enomoto N, Yoneda M, Murata K, Ito K, Koike K, Mizokami M. Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C. J Gastroenterol Hepatol 2014;29:1996-2005. [PMID: 24910341 DOI: 10.1111/jgh.12646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
57 Yan Z, Fan K, Fan Y, Wang X, Mao Q, Deng G, Wang Y. Thyroid dysfunction in chinese patients with chronic hepatitis C treated with interferon alpha: incidence, long-term outcome and predictive factors. Hepat Mon 2012;12:e6390. [PMID: 23087763 DOI: 10.5812/hepatmon.6390] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
58 Horner SM, Naggie S. Successes and Challenges on the Road to Cure Hepatitis C. PLoS Pathog. 2015;11:e1004854. [PMID: 26087286 DOI: 10.1371/journal.ppat.1004854] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
59 Morikawa K, Nakamura A, Shimazaki T, Sakamoto N. Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence. Drug Des Devel Ther 2018;12:2749-56. [PMID: 30233138 DOI: 10.2147/DDDT.S133697] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
60 Qing S, Ji D, Li B, Li F, Wang Y, Niu X, Ling B, Meng Y, Lau G, Chen G. Improvement of glucose and lipid metabolism with pegylated interferon-a plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus. Ann Saudi Med 2015;35:293-7. [PMID: 26497709 DOI: 10.5144/0256-4947.2015.293] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
61 Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver Int. 2013;33 Suppl 1:68-79. [PMID: 23286849 DOI: 10.1111/liv.12063] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
62 Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206. [PMID: 21449783 DOI: 10.1056/NEJMoa1010494] [Cited by in Crossref: 1849] [Cited by in F6Publishing: 729] [Article Influence: 168.1] [Reference Citation Analysis]
63 Menon RM, Klein CE, Podsadecki TJ, Chiu YL, Dutta S, Awni WM. Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharmacol 2016;81:929-40. [PMID: 26710243 DOI: 10.1111/bcp.12873] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
64 Need AC, Goldstein DB. Whole genome association studies in complex diseases: where do we stand? Dialogues Clin Neurosci 2010;12:37-46. [PMID: 20373665 [PMID: 20373665 DOI: 10.31887/dcns.2010.12.1/aneed] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
65 D'Ambrosio R, Aghemo A. Treatment of patients with HCV related cirrhosis: many rewards with very few risks. Hepat Mon 2012;12:361-8. [PMID: 22879824 DOI: 10.5812/hepatmon.6095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
66 Saludes V, Bascuñana E, Jordana-Lluch E, Casanovas S, Ardèvol M, Soler E, Planas R, Ausina V, Martró E. Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients. PLoS One 2013;8:e72600. [PMID: 24015264 DOI: 10.1371/journal.pone.0072600] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
67 Berger CT, Kim AY. IL28B polymorphisms as a pretreatment predictor of response to HCV treatment. Infect Dis Clin North Am 2012;26:863-77. [PMID: 23083820 DOI: 10.1016/j.idc.2012.08.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
68 Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010;70:147-165. [PMID: 20108989 DOI: 10.2165/11531990-000000000-00000] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
69 Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R;  HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-1217. [PMID: 21449784 DOI: 10.1056/nejmoa1009482] [Cited by in Crossref: 1225] [Cited by in F6Publishing: 439] [Article Influence: 111.4] [Reference Citation Analysis]
70 Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Clin Microbiol Rev 2017;30:23-42. [PMID: 27795306 DOI: 10.1128/CMR.00037-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
71 Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850-8. [PMID: 23836235 DOI: 10.1038/nm.3184] [Cited by in Crossref: 205] [Cited by in F6Publishing: 199] [Article Influence: 22.8] [Reference Citation Analysis]
72 Wu C, Gilroy R, Taylor R, Olyaee M, Abdulkarim B, Forster J, O’Neil M, Damjanov I, Wan YJ. Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. Hepatology. 2011;54:1966-1974. [PMID: 21898497 DOI: 10.1002/hep.24645] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
73 Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. A human claudin-1-derived peptide inhibits hepatitis C virus entry. Hepatology. 2012;56:507-515. [PMID: 22378192 DOI: 10.1002/hep.25685] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
74 Cai Q, Zhang X, Lin C, Shao X, Guan Y, Deng H, Wei M, Huang M, Ren Z, Lu L, Mei Y, Xu M, Zhu J, Shi H, Lin G, Liu Y, Hu F, Luo Q, Lan Y, Guo F, Zhao Z, Gao Z. 24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial. PLoS One 2015;10:e0140853. [PMID: 26509605 DOI: 10.1371/journal.pone.0140853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
75 Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Iio S, Oshita M, Hagiwara H, Mita E, Inui Y, Hijioka T, Inada M, Tamura S, Yoshihara H, Inoue A, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Hayashi N, Takehara T. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1. J Gastroenterol 2014;49:737-47. [PMID: 23689988 DOI: 10.1007/s00535-013-0824-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
76 Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Kaneko A, Hagiwara H, Mita E, Ito T, Nagase T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Imai Y, Kato M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. J Gastroenterol 2011;46:944-52. [PMID: 21552988 DOI: 10.1007/s00535-011-0403-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
77 Mechie NC, Röver C, Cameron S, Amanzada A. Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. World J Hepatol 2014; 6(10): 759-765 [PMID: 25349647 DOI: 10.4254/wjh.v6.i10.759] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
78 Picchio G, De Meyer S, Dierynck I, Ghys A, Gritz L, Kieffer TL, Bartels DJ, Witek J, Bengtsson L, Luo D, Kauffman RS, Adda N, Sarrazin C. Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection. J Clin Virol 2014;59:148-55. [PMID: 24462470 DOI: 10.1016/j.jcv.2013.12.011] [Reference Citation Analysis]
79 Du NN, Peng ZG, Bi CW, Tang S, Li YH, Li JR, Zhu YP, Zhang JP, Wang YX, Jiang JD. N-substituted benzyl matrinic acid derivatives inhibit hepatitis C virus (HCV) replication through down-regulating host heat-stress cognate 70 (Hsc70) expression. PLoS One. 2013;8:e58675. [PMID: 23516533 DOI: 10.1371/journal.pone.0058675] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
80 McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, Levine S, Chaniewski S, Yu F, Barry D. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012;56:5387-5396. [PMID: 22869577 DOI: 10.1128/aac.01186-12] [Cited by in Crossref: 146] [Cited by in F6Publishing: 53] [Article Influence: 14.6] [Reference Citation Analysis]
81 Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, Edlin BR, Mermin J, Ward JW, Ryerson AB. Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016. Hepatology 2019;69:1020-31. [PMID: 30398671 DOI: 10.1002/hep.30297] [Cited by in Crossref: 171] [Cited by in F6Publishing: 155] [Article Influence: 42.8] [Reference Citation Analysis]
82 Yang H, Robinson M, Corsa AC, Peng B, Cheng G, Tian Y, Wang Y, Pakdaman R, Shen M, Qi X, Mo H, Tay C, Krawczyk S, Sheng XC, Kim CU, Yang C, Delaney WE 4th. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Antimicrob Agents Chemother 2014;58:647-53. [PMID: 23939899 DOI: 10.1128/AAC.00487-13] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
83 Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850-8. [PMID: 23836235 DOI: 10.1038/nm.3184] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Singal AK, Jampana SC, Anand BS. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig Dis Sci. 2011;56:2221-2226. [PMID: 21643737 DOI: 10.1007/s10620-011-1765-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
85 Dill MT, Makowska Z, Trincucci G, Gruber AJ, Vogt JE, Filipowicz M, Calabrese D, Krol I, Lau DT, Terracciano L, van Nimwegen E, Roth V, Heim MH. Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation. J Clin Invest 2014;124:1568-81. [PMID: 24569457 DOI: 10.1172/JCI70408] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
86 Shao RX, Zhang L, Hong Z, Goto K, Cheng D, Chen WC, Jilg N, Kumthip K, Fusco DN, Peng LF, Chung RT. SOCS1 abrogates IFN's antiviral effect on hepatitis C virus replication. Antiviral Res 2013;97:101-7. [PMID: 23237992 DOI: 10.1016/j.antiviral.2012.12.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
87 Vugmeyster Y, Harrold J, Xu X. Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions. AAPS J 2012;14:714-27. [PMID: 22798020 DOI: 10.1208/s12248-012-9385-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
88 Evon DM, Golin CE, Fried MW, Keefe FJ. Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? J Consult Clin Psychol 2013;81:361-74. [PMID: 22730952 DOI: 10.1037/a0029030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
89 Bienvenu LA, Noonan J, Wang X, Peter K. Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. Cardiovasc Res 2020;116:2197-206. [PMID: 33063089 DOI: 10.1093/cvr/cvaa284] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
90 Sharma SA, Feld JJ. Management of HCV in cirrhosis-a rapidly evolving landscape. Curr Gastroenterol Rep 2015;17:443. [PMID: 25896437 DOI: 10.1007/s11894-015-0443-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
91 Jou JH, Sulkowski MS, Noviello S, Long J, Pedicone LD, McHutchison JG, Muir AJ. Analysis of site performance in academic-based and community-based centers in the IDEAL Study. J Clin Gastroenterol 2013;47:e91-5. [PMID: 23787248 DOI: 10.1097/MCG.0b013e318294baa4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
92 Jazwinski AB, Clark PJ, Thompson AJ, Gordon SC, Lawitz EJ, Noviello S, Brass CA, Pedicone LD, Albrecht JK, Sulkowski MS, Muir AJ. Predictors of consent to pharmacogenomics testing in the IDEAL study. Pharmacogenet Genomics 2013;23:619-23. [PMID: 24061202 DOI: 10.1097/FPC.0000000000000002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
93 Grandi T, da Silva CM, Amaral KM, Picon PD, Costi C, da Fré NN, Fiegenbaum M, Niel C, Rossetti ML. Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene. Mem Inst Oswaldo Cruz 2013;108:48-53. [PMID: 23440114 DOI: 10.1590/s0074-02762013000100008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
94 Al-Anazi MR, Matou-Nasri S, Abdo AA, Sanai FM, Alkahtani S, Alarifi S, Alkahtane AA, Al-Yahya H, Ali D, Alessia MS, Alshahrani B, Al-Ahdal MN, Al-Qahtani AA. Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection. J Immunol Res 2017;2017:1590653. [PMID: 28127569 DOI: 10.1155/2017/1590653] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
95 Kulkeaw K, Pengsart W. Progress and Challenges in the Use of a Liver-on-a-Chip for Hepatotropic Infectious Diseases. Micromachines (Basel) 2021;12:842. [PMID: 34357252 DOI: 10.3390/mi12070842] [Reference Citation Analysis]
96 Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol 2015; 7(12): 1617-1631 [PMID: 26140082 DOI: 10.4254/wjh.v7.i12.1617] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]
97 Pearlman BL. The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection. Curr Gastroenterol Rep 2011;13:78-86. [PMID: 21080244 DOI: 10.1007/s11894-010-0161-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
98 Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Sheridan P, Persson A, Huang SP, Hernandez D, Sheaffer AK, Scola P, Marbury T, Lawitz E, Goldwater R, Rodriguez-Torres M, Demicco M, Wright D, Charlton M, Kraft WK, Lopez-Talavera JC, Grasela DM. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother 2012;56:1838-44. [PMID: 22290978 DOI: 10.1128/AAC.05854-11] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 3.9] [Reference Citation Analysis]
99 Stern C, Martinot-Peignoux M, Ripault MP, Boyer N, Castelnau C, Valla D, Marcellin P. Impact of ribavirin dose on retreatment of chronic hepatitis C patients. World J Gastroenterol 2012; 18(23): 2966-2972 [PMID: 22736920 DOI: 10.3748/wjg.v18.i23.2966] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
100 El Raziky M, Fathalah WF, El-Akel WA, Salama A, Esmat G, Mabrouk M, Salama RM, Khatab HM. The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study. Hepat Mon. 2013;13:e10069. [PMID: 23922556 DOI: 10.5812/hepatmon.10069] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
101 Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis. 2012;12:357. [PMID: 23245594 DOI: 10.1186/1471-2334-12-357] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
102 Daneshvar M, Nikbin M, Talebi S, Javadi F, Aghasadeghi MR, Mahmazi S, Sadat SM. Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C. Iran Red Crescent Med J 2016;18:e28566. [PMID: 28144454 DOI: 10.5812/ircmj.28566] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
103 Hagan LM, Wolpe PR, Schinazi RF. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 2013;21:625-33. [PMID: 24238778 DOI: 10.1016/j.tim.2013.09.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
104 Mandrik O, Knies S, Golubovska O, Duda O, Dudar L, Fedorchenko S, Zaliska O, Hans Severens JL. Cost comparison of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine. Open Med (Wars) 2015;10:25-33. [PMID: 28352673 DOI: 10.1515/med-2015-0006] [Reference Citation Analysis]
105 Pattullo V, Heathcote EJ, Wong DK. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatol Int. 2010;4:723-731. [PMID: 21286343 DOI: 10.1007/s12072-010-9207-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
106 Toyota J, Karino Y, Suzuki F, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, Hu W, McPhee F, Linaberry M, Yin PD, Swenson ES, Kumada H. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol 2017;52:385-95. [PMID: 27502287 DOI: 10.1007/s00535-016-1245-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
107 Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, Mehrnoush L, Fatemi A. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon. 2012;12:e8387. [PMID: 23550102 DOI: 10.5812/hepatmon.8387] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
108 Druyts E, Mills EJ, Nachega J, O'Regan C, Cooper CL. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol 2012;5:11-21. [PMID: 22427726 DOI: 10.2147/CEG.S28253] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
109 De Clercq E. Ebola virus (EBOV) infection: Therapeutic strategies. Biochem Pharmacol 2015;93:1-10. [PMID: 25481298 DOI: 10.1016/j.bcp.2014.11.008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
110 Gidwani R, Barnett PG, Goldhaber-Fiebert JD, Asch SM, Lo J, Dally SK, Owens DK. Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans. J Viral Hepat 2015;22:489-95. [PMID: 25417805 DOI: 10.1111/jvh.12344] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
111 Scott J, Rosa K, Fu M, Cerri K, Peeters M, Beumont M, Zeuzem S, Evon DM, Gilles L. Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2014;14:465. [PMID: 25164700 DOI: 10.1186/1471-2334-14-465] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
112 Mkuu RS, Shenkman EA, Muller KE, Huo T, Salloum RG, Cabrera R, Zarrinpar A, Thomas E, Szurek SM, Nelson DR. Do patients at high risk for Hepatitis C receive recommended testing? A retrospective cohort study of statewide Medicaid claims linked with OneFlorida clinical data. Medicine 2021;100:e28316. [DOI: 10.1097/md.0000000000028316] [Reference Citation Analysis]
113 Molina-Cuadrado E, Mateo-Carrrasco H, Collado A, Casado Martín M. Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents. Eur J Hosp Pharm 2018;25:132-7. [PMID: 31157007 DOI: 10.1136/ejhpharm-2017-001277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
114 Al-Qahtani A, Al-Anazi M, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA, Al-Ashgar HI, Khan MQ, Albenmousa A, Khalaf N, Viswan N, Al-Ahdal MN. Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection. J Immunol Res 2015;2015:768470. [PMID: 25811035 DOI: 10.1155/2015/768470] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
115 Friedman RM, Contente S. Interferons as Therapy for Viral and Neoplastic Diseases: From Panacea to Pariah to Paragon. Pharmaceuticals (Basel) 2009;2:206-16. [PMID: 27713234 DOI: 10.3390/ph2030206] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
116 Sperl J, Frankova S, Senkerikova R, Neroldova M, Hejda V, Volfova M, Merta D, Viklicky O, Spicak J, Jirsa M. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection. World J Gastroenterol 2015; 21(18): 5496-5504 [PMID: 25987772 DOI: 10.3748/wjg.v21.i18.5496] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
117 Potluri VS, Goldberg DS, Mohan S, Bloom RD, Sawinski D, Abt PL, Blumberg EA, Parikh CR, Sharpe J, Reddy KR, Molnar MZ, Sise M, Reese PP. National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys. J Am Soc Nephrol. 2019;30:1939-1951. [PMID: 31515244 DOI: 10.1681/asn.2019050462] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
118 Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401. [PMID: 19684573 DOI: 10.1038/nature08309] [Cited by in Crossref: 2619] [Cited by in F6Publishing: 2430] [Article Influence: 201.5] [Reference Citation Analysis]
119 Chen CH, Chen CH, Lin CL, Lin CY, Hu TH, Tung SY, Hsieh SY, Lu SN, Chien RN, Hung CH, Sheen IS. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. Sci Rep 2019;9:7086. [PMID: 31068655 DOI: 10.1038/s41598-019-43554-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
120 Zhu Y, Chen S. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol 2013; 19(47): 8963-8973 [PMID: 24379621 DOI: 10.3748/wjg.v19.i47.8963] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
121 Lu YF, Goldstein DB, Urban TJ, Bradrick SS. Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. Virology 2015;476:334-40. [PMID: 25577150 DOI: 10.1016/j.virol.2014.12.020] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
122 Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM. Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:713-728. [PMID: 24019151 DOI: 10.1038/nrgastro.2013.163] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
123 Li Y, Peng Z, Hao L, Wu Z, Zhu Y, Hu L, Jiang J, Li Z. Synthesis of novel substituted N-aryl benzamides as hA3G stabilizers and their inhibitory activities against hepatitis C virus replication. Acta Pharmaceutica Sinica B 2013;3:312-21. [DOI: 10.1016/j.apsb.2013.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
124 Wong WWL, Tu HA, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ 2015;187:E110-21. [PMID: 25583667 DOI: 10.1503/cmaj.140711] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
125 Roccatello D, Sciascia S, Rossi D, Solfietti L, Fenoglio R, Menegatti E, Baldovino S. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. Oncotarget 2017;8:41764-77. [PMID: 28454112 DOI: 10.18632/oncotarget.16986] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
126 O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM; HALT-C Trial Group. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One 2011;6:e20904. [PMID: 21760886 DOI: 10.1371/journal.pone.0020904] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
127 Clark PJ, Thompson AJ, Zhu M, Vock DM, Zhu Q, Ge D, Patel K, Harrison SA, Urban TJ, Naggie S, Fellay J, Tillmann HL, Shianna K, Noviello S, Pedicone LD, Esteban R, Kwo P, Sulkowski MS, Afdhal N, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ; IDEAL investigators. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. J Viral Hepat. 2012;19:332-340. [PMID: 22497812 DOI: 10.1111/j.1365-2893.2011.01553.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
128 Jung CH, Um SH, Kim TH, Yim SY, Suh SJ, Yim HJ, Seo YS, Choi HS, Chun HJ. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C. Gut Liver 2016;10:808-17. [PMID: 27114417 DOI: 10.5009/gnl15360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
129 Murphy AA, Herrmann E, Osinusi AO, Wu L, Sachau W, Lempicki RA, Yang J, Chung TL, Wood BJ, Haagmans BL. Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. AIDS. 2011;25:1179-1187. [PMID: 21593619 DOI: 10.1097/qad.0b013e3283471d53] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
130 Thompson AJ, Clark PJ, Singh A, Ge D, Fellay J, Zhu M, Zhu Q, Urban TJ, Patel K, Tillmann HL. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol. 2012;56:313-319. [PMID: 21703177 DOI: 10.1016/j.jhep.2011.04.021] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
131 Proeschold-Bell RJ, Patkar AA, Naggie S, Coward L, Mannelli P, Yao J, Bixby P, Muir AJ. An integrated alcohol abuse and medical treatment model for patients with hepatitis C. Dig Dis Sci. 2012;57:1083-1091. [PMID: 22134784 DOI: 10.1007/s10620-011-1976-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
132 Jiang Z, Wang H, Li Y, Peng Z, Li Y, Li Z. Synthesis and antiviral activity of a series of novel N-phenylbenzamide and N-phenylacetophenone compounds as anti-HCV and anti-EV71 agents. Acta Pharm Sin B 2015;5:201-9. [PMID: 26579447 DOI: 10.1016/j.apsb.2015.03.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
133 Liu CH, Huang CF, Liu CJ, Dai CY, Huang JF, Lin JW, Liang CC, Yang SS, Lin CL, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Kao JH, Yu ML. Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. Sci Rep 2015;5:11710. [PMID: 26130141 DOI: 10.1038/srep11710] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
134 Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol 2012;26:205-10. [PMID: 22506260 DOI: 10.1155/2012/751057] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
135 Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother. 2012;23:1-12. [PMID: 22592135 DOI: 10.3851/imp2125] [Cited by in Crossref: 68] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
136 Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, Neri S, Malaguarnera M, Volti GL, Galvano F. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol 2011; 17(39): 4414-4420 [PMID: 22110268 DOI: 10.3748/wjg.v17.i39.4414] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
137 Wieczorek-Godlewska R, Płoski R, Perkowska-Ptasińska A, Tronina O, Sadowska A, Pacholczyk M, Lisik W, Durlik M. The impact of the recipient and donor interferon lambda-3 polymorphism on the course of HCV infection following liver transplantation. Clin Exp Hepatol 2017;3:152-8. [PMID: 29062905 DOI: 10.5114/ceh.2017.68401] [Reference Citation Analysis]
138 Smith AK, Simon JS, Gustafson EL, Noviello S, Cubells JF, Epstein MP, Devlin DJ, Qiu P, Albrecht JK, Brass CA, Sulkowski MS, McHutchinson JG, Miller AH. Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C. Mol Psychiatry 2012;17:781-9. [PMID: 21691274 DOI: 10.1038/mp.2011.67] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 5.0] [Reference Citation Analysis]
139 Thomas DL. Curing hepatitis C with pills: a step toward global control. Lancet 2010;376:1441-2. [PMID: 20951421 DOI: 10.1016/S0140-6736(10)61497-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
140 Oh IS, Won JW, Kim HJ, Lee HW. Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection. Korean J Intern Med 2017;32:1010-7. [PMID: 28797159 DOI: 10.3904/kjim.2016.405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
141 Scaggiante R, Chemello L, Rinaldi R, Bartolucci GB, Trevisan A. Acute hepatitis C virus infection in a nurse trainee following a needlestick injury. World J Gastroenterol 2013; 19(4): 581-585 [PMID: 23382640 DOI: 10.3748/wjg.v19.i4.581] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
142 Dozier JK, Distefano MD. Site-Specific PEGylation of Therapeutic Proteins. Int J Mol Sci 2015;16:25831-64. [PMID: 26516849 DOI: 10.3390/ijms161025831] [Cited by in Crossref: 142] [Cited by in F6Publishing: 121] [Article Influence: 20.3] [Reference Citation Analysis]
143 Nakamura M, Kanda T, Miyamura T, Wu S, Nakamoto S, Yokosuka O. Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment. Int J Med Sci 2013;10:1015-21. [PMID: 23801888 DOI: 10.7150/ijms.6402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
144 Hou J, van Oord G, Groothuismink ZM, Claassen MA, Kreefft K, Zaaraoui-Boutahar F, van IJcken WF, Osterhaus AD, Janssen HL, Andeweg AC, de Knegt RJ, Boonstra A. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection. J Virol 2014;88:12254-64. [PMID: 25100847 DOI: 10.1128/JVI.00775-14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
145 Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. World J Gastroenterol 2014; 20(44): 16726-16733 [PMID: 25469044 DOI: 10.3748/wjg.v20.i44.16726] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
146 Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Voss F, Baum P, Gallivan JP, Böcher WO, Mensa FJ. ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS One 2015;10:e0144004. [PMID: 26650626 DOI: 10.1371/journal.pone.0144004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
147 Dieterich D, Asselah T, Guyader D, Berg T, Schuchmann M, Mauss S, Ratziu V, Ferenci P, Larrey D, Maieron A, Stern JO, Ozan M, Datsenko Y, Böcher WO, Steinmann G. SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients. Antimicrob Agents Chemother 2014;58:3429-36. [PMID: 24709256 DOI: 10.1128/AAC.02497-13] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
148 Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, Rosenthal P, Mohan P, Balistreri WF, Narkewicz MR, Smith L, Lobritto SJ, Rossi S, Valsamakis A, Goodman Z, Robuck PR, Barton BA; Peds-C Clinical Research Network. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450-458.e1. [PMID: 21036173 DOI: 10.1053/j.gastro.2010.10.047] [Cited by in Crossref: 95] [Cited by in F6Publishing: 80] [Article Influence: 7.9] [Reference Citation Analysis]
149 Liu D, Ndongwe TP, Puray-Chavez M, Casey MC, Izumi T, Pathak VK, Tedbury PR, Sarafianos SG. Effect of P-body component Mov10 on HCV virus production and infectivity. FASEB J 2020;34:9433-49. [PMID: 32496609 DOI: 10.1096/fj.201800641R] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
150 Uhl P, Fricker G, Haberkorn U, Mier W. Current status in the therapy of liver diseases. Int J Mol Sci. 2014;15:7500-7512. [PMID: 24786290 DOI: 10.3390/ijms15057500] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
151 Miyase S, Haraoka K, Ouchida Y, Morishita Y, Fujiyama S. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients. J Gastroenterol 2012;47:1014-21. [PMID: 22382633 DOI: 10.1007/s00535-012-0560-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
152 Kwo PY, Puenpatom A, Zhang Z, Hui SL, Kelley AA, Muschi D. Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. PLoS One 2019;14:e0218759. [PMID: 31437170 DOI: 10.1371/journal.pone.0218759] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
153 Lara J, Khudyakov Y. Epistatic connectivity among HCV genomic sites as a genetic marker of interferon resistance. Antivir Ther 2012;17:1471-5. [PMID: 23321567 DOI: 10.3851/IMP2478] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
154 Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One 2013;8:e58975. [PMID: 23533595 DOI: 10.1371/journal.pone.0058975] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 5.2] [Reference Citation Analysis]
155 Zhang L, Gwinn M, Hu DJ. Viral hepatitis C gets personal--the value of human genomics to public health. Public Health Genomics. 2013;16:192-197. [PMID: 23859951 DOI: 10.1159/000352014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
156 Salvatierra K, Florez H. Biomedical Mutation Analysis (BMA): A software tool for analyzing mutations associated with antiviral resistance. F1000Res 2016;5:1141. [PMID: 27547378 DOI: 10.12688/f1000research.8740.2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Xiao N, Shi S, Zhuang H. A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection. Hepat Med 2010;2:99-109. [PMID: 24367210 DOI: 10.2147/hmer.s11916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
158 Gonzalez SA. Consensus interferon: tailored therapy and the impact of adherence. Dig Dis Sci 2011;56:631-4. [PMID: 21259073 DOI: 10.1007/s10620-011-1563-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
159 Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2010;7:485-94. [PMID: 20644567 DOI: 10.1038/nrgastro.2010.101] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]
160 Dong J, Wu T, Zhang Y, Xie Z, He J. Transcriptome and MicroRNAs Profiling Analysis of Huh7.5.1 Cells in Response to Hepatitis C Virus Infection. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.118724] [Reference Citation Analysis]
161 Han QY, Liu ZW. Current treatment of chronic hepatitis C in China: Dilemma and potential problems. World J Gastroenterol 2016; 22(19): 4615-4618 [PMID: 27217693 DOI: 10.3748/wjg.v22.i19.4615] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
162 Afdhal NH. Hepatitis C viral infection in difficult-to-treat populations: An overview. Clin Liver Dis (Hoboken) 2012;1:63-4. [PMID: 31186850 DOI: 10.1002/cld.57] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
163 Gane EJ, Rouzier R, Wiercinska-Drapalo A, Larrey DG, Morcos PN, Brennan BJ, Le Pogam S, Nájera I, Petric R, Tran JQ, Kulkarni R, Zhang Y, Smith P, Yetzer ES, Shulman NS. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders. Antimicrob Agents Chemother 2014;58:1136-45. [PMID: 24295986 DOI: 10.1128/AAC.01515-13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
164 Berg KT, Nelson B, Harrison AR, McLoon LK, Lee MS. Pegylated interferon alpha-associated optic neuropathy. J Neuroophthalmol 2010;30:117-22. [PMID: 20351572 DOI: 10.1097/WNO.0b013e3181d8e4af] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
165 Aligeti M, Roder A, Horner SM. Cooperation between the Hepatitis C Virus p7 and NS5B Proteins Enhances Virion Infectivity. J Virol 2015;89:11523-33. [PMID: 26355084 DOI: 10.1128/JVI.01185-15] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
166 Gara N, Ghany MG. What the infectious disease physician needs to know about pegylated interferon and ribavirin. Clin Infect Dis 2013;56:1629-36. [PMID: 23429551 DOI: 10.1093/cid/cit074] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
167 Clark PJ, Thompson AJ, Zhu Q, Vock DM, Zhu M, Patel K, Harrison SA, Naggie S, Ge D, Tillmann HL. The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci. 2012;57:2213-2221. [PMID: 22543885 DOI: 10.1007/s10620-012-2171-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
168 de Leuw P, Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect Dis 2017;5:Doc08. [PMID: 30671330 DOI: 10.3205/id000034] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
169 Wong WW, Lee KM, Singh S, Wells G, Feld JJ, Krahn M. Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. CMAJ Open 2017;5:E97-E108. [PMID: 28401125 DOI: 10.9778/cmajo.20160161] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
170 Yang Y, Dang SS. Safety of direct antiviral agents for treatment of hepatitis C virus infection. Shijie Huaren Xiaohua Zazhi 2017; 25(8): 659-669 [DOI: 10.11569/wcjd.v25.i8.659] [Reference Citation Analysis]
171 Hu J, Doucette K, Hartling L, Tjosvold L, Robinson J. Treatment of hepatitis C in children: a systematic review. PLoS One. 2010;5:e11542. [PMID: 20644626 DOI: 10.1371/journal.pone.0011542] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
172 Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798-801. [PMID: 19759533 DOI: 10.1038/nature08463] [Cited by in Crossref: 1559] [Cited by in F6Publishing: 1474] [Article Influence: 119.9] [Reference Citation Analysis]
173 El-Shamy A, Eng FJ, Doyle EH, Klepper AL, Sun X, Sangiovanni A, Iavarone M, Colombo M, Schwartz RE, Hoshida Y, Branch AD. A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. J Hepatol 2015;63:1323-33. [PMID: 26220749 DOI: 10.1016/j.jhep.2015.07.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
174 Deborah Friedman N, Green JH, Weber HM, Stephen S, Lane SE, Ting AY, Watson JP. Hepatitis C virus treatment in the 'real-world': how well do 'real' patients respond? J Clin Exp Hepatol 2014;4:214-20. [PMID: 25755563 DOI: 10.1016/j.jceh.2014.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
175 Ho SB, Aqel B, Dieperink E, Liu S, Tetrick L, Falck-Ytter Y, DeComarmond C, Smith CI, McKee DP, Boyd W, Kulig CC, Bini EJ, Pedrosa MC. U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients. Dig Dis Sci 2011;56:880-8. [PMID: 21221804 DOI: 10.1007/s10620-010-1504-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
176 Hu X, Jiang Y, Li X, Gao Y, Guo X, Chi X, Yan H, Feng J, Zhong J, Sun B, Shao X, Xiao W, Pan Y, Niu J. Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection. J Interferon Cytokine Res 2014;34:366-75. [PMID: 24367931 DOI: 10.1089/jir.2013.0049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
177 Aizawa N, Enomoto H, Takashima T, Sakai Y, Iwata K, Ikeda N, Tanaka H, Iwata Y, Saito M, Imanishi H. Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2014;49:1253-1263. [PMID: 24065124 DOI: 10.1007/s00535-013-0884-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
178 Pietrosi G, Russelli G, Barbera F, Curcio G, Tuzzolino F, Gallo A, Volpes R, Vizzini G, Conaldi PG. Direct-acting antivirals ability to clear intestinal HCV-RNA in liver transplant patients. Transpl Infect Dis 2020;22:e13345. [PMID: 32495971 DOI: 10.1111/tid.13345] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
179 Bax HI, Freeman AF, Ding L, Hsu AP, Marciano B, Kristosturyan E, Jancel T, Spalding C, Pechacek J, Olivier KN, Barnhart LA, Boris L, Frein C, Claypool RJ, Anderson V, Zerbe CS, Holland SM, Sampaio EP. Interferon alpha treatment of patients with impaired interferon gamma signaling. J Clin Immunol 2013;33:991-1001. [PMID: 23512243 DOI: 10.1007/s10875-013-9882-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
180 Huang CQ, Wang FX. Progress in research of genotypes of hepatitis C virus. Shijie Huaren Xiaohua Zazhi 2012; 20(35): 3529-3535 [DOI: 10.11569/wcjd.v20.i35.3529] [Reference Citation Analysis]
181 Melis R, Fauron C, McMillin G, Lyon E, Shirts B, Hubley LM, Slev PR. Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. J Mol Diagn 2011;13:446-51. [PMID: 21704279 DOI: 10.1016/j.jmoldx.2011.03.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
182 Park SH, Park CK, Lee JW, Kim YS, Jeong SH, Kim YS, Kim JH, Hwang SG, Rim KS, Yim HJ, Cheong JY, Cho SW, Lee JS, Park YM, Jang JW, Lee CK, Shon JH, Yang JM, Ju YS. Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. Gut Liver 2012;6:98-106. [PMID: 22375178 DOI: 10.5009/gnl.2012.6.1.98] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
183 Porter JC, Lusk HM, Katz AR. Prevalence of HCV infection among clients in community-based health settings in Hawaii, 2002-2010: assessing risk factors. Am J Public Health 2014;104:1534-9. [PMID: 24028267 DOI: 10.2105/AJPH.2013.301282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
184 Myers RP, Cooper C, Sherman M, Lalonde R, Witt-Sullivan H, Elkashab M, Harris P, Balshaw R, Usaty C, Marrotta PJ. Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). Can J Gastroenterol 2011;25:503-10. [PMID: 21912762 DOI: 10.1155/2011/698780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
185 Noureddin M, Ghany MG. Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C. Gastroenterol Clin North Am 2010;39:649-58. [PMID: 20951922 DOI: 10.1016/j.gtc.2010.08.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
186 Amanzada A, Goralczyk AD, Reinhardt L, Moriconi F, Cameron S, Mihm S. Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy. BMC Infect Dis 2014;14:503. [PMID: 25227310 DOI: 10.1186/1471-2334-14-503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
187 Funk EK, Shaffer A, Shivakumar B, Sneller M, Polis MA, Masur H, Heytens L, Nelson A, Kwan R, Kottilil S, Kohli A. Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. AIDS Res Hum Retroviruses 2013;29:1190-4. [PMID: 23701022 DOI: 10.1089/aid.2013.0035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
188 Gürbüz Y, Tülek NE, Tütüncü EE, Koruk ST, Aygen B, Demirtürk N, Kınıklı S, Kaya A, Yıldırmak T, Süer K, Korkmaz F, Ural O, Akhan S, Günal Ö, Tuna N, Köse Ş, Gönen İ, Örmen B, Türker N, Saltoğlu N, Batırel A, Tuncer G, Bulut C, Sırmatel F, Ulçay A, Karagöz E, Tosun D, Şener A, Aynıoğlu A, Altunok ES. Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study. Balkan Med J 2016;33:18-26. [PMID: 26966614 DOI: 10.5152/balkanmedj.2015.15859] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
189 Kim DY. Hepatitis C viral kinetics as a determinant of stopping pegylated interferon and ribavirin in genotype 1 infection. Gut Liver 2014;8:335-6. [PMID: 25071896 DOI: 10.5009/gnl.2014.8.4.335] [Reference Citation Analysis]
190 Bastos JCS, Padilla MA, Caserta LC, Miotto N, Vigani AG, Arns CW. Hepatitis C virus: Promising discoveries and new treatments. World J Gastroenterol 2016; 22(28): 6393-6401 [PMID: 27605875 DOI: 10.3748/wjg.v22.i28.6393] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
191 Sporea I, Popescu A, Curescu M, Sirli R, Dan I, Goldis A, Gradinaru O, Ardelean M, Danila M, Bota S, Deleanu A. The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C. Hepat Mon 2011;11:975-9. [PMID: 22368681 DOI: 10.5812/kowsar.1735143x.4202] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
192 Naing C, Sitt T, Aung AT, Aung K. Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study. Medicine (Baltimore). 2015;94:e1234. [PMID: 26222859 DOI: 10.1097/md.0000000000001234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
193 Ding YH, Liu B, Zhang X, Sun L, Zhang H, Luo H, Sun YF, Liu CJ, Zhang Q, Cao YC, Chen H, Niu JQ. Tolerability and efficacy of pegylated consensus interferon-α in the treatment of chronic hepatitis C. Exp Ther Med 2017;13:9-16. [PMID: 28123460 DOI: 10.3892/etm.2016.3914] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
194 Salem ML, El-Badawy A. Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World J Hepatol 2015; 7(23): 2449-2458 [PMID: 26483866 DOI: 10.4254/wjh.v7.i23.2449] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
195 Borgia SM, Rowaiye A. Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada. Can J Gastroenterol Hepatol 2015;29:125-9. [PMID: 25855874 DOI: 10.1155/2015/591260] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
196 Yang Z, Zhuang L, Yang L, Chen X. Efficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials. Gastroenterol Res Pract. 2013;2013:739029. [PMID: 23662098 DOI: 10.1155/2013/739029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
197 Dogan UB, Akin MS, Yalaki S. Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment. World J Gastroenterol 2013; 19(46): 8678-8686 [PMID: 24379586 DOI: 10.3748/wjg.v19.i46.8678] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
198 Cento V, Mirabelli C, Salpini R, Dimonte S, Artese A, Costa G, Mercurio F, Svicher V, Parrotta L, Bertoli A. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One. 2012;7:e39652. [PMID: 22792183 DOI: 10.1371/journal.pone.0039652] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 6.4] [Reference Citation Analysis]
199 Liu S, Barnett PG, Holodniy M, Lo J, Joyce VR, Gidwani R, Asch SM, Owens DK, Goldhaber-Fiebert JD. Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations. MDM Policy Pract 2016;1. [PMID: 29756049 DOI: 10.1177/2381468316671946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
200 Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212-223. [PMID: 21386812 DOI: 10.1038/nrgastro.2011.21] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 8.5] [Reference Citation Analysis]
201 Carrion AF, Gutierrez J, Martin P. New antiviral agents for the treatment of hepatitis C: ABT-450. Expert Opin Pharmacother. 2014;15:711-716. [PMID: 24517400 DOI: 10.1517/14656566.2014.889116] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
202 Binka M, Janjua NZ, Grebely J, Estes C, Schanzer D, Kwon JA, Shoukry NH, Kwong JC, Razavi H, Feld JJ, Krajden M. Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model. JAMA Netw Open 2020;3:e204192. [PMID: 32374397 DOI: 10.1001/jamanetworkopen.2020.4192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
203 Mata-Marín JA, Fuentes-Allen JL, Gaytán-Martínez J, Manjarrez-Téllez B, Chaparro-Sánchez A, Arroyo-Anduiza CI. APRI as a predictor of early viral response in chronic hepatitis C patients. World J Gastroenterol 2009; 15(39): 4923-4927 [PMID: 19842223 DOI: 10.3748/wjg.15.4923] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
204 Xu C, Gupta S, Krishna G, Cutler D, Wirth S, Galoppo C, Ciocca M, Kolz K, Noviello S, Sniukiene V. Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. Eur J Clin Pharmacol 2013;69:2045-54. [PMID: 23975236 DOI: 10.1007/s00228-013-1574-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
205 Barros FM, Cheinquer H, Tsuchiya CT, Santos EA. Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil. Cost Eff Resour Alloc. 2013;11:25. [PMID: 24103591 DOI: 10.1186/1478-7547-11-25] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
206 Buettner N, Thimme R. Sexual dimorphism in hepatitis B and C and hepatocellular carcinoma. Semin Immunopathol 2019;41:203-11. [PMID: 30498927 DOI: 10.1007/s00281-018-0727-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
207 Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. Sofosbuvir and ABT-450: Terminator of hepatitis C virus? World J Gastroenterol 2013; 19(21): 3199-3206 [PMID: 23745021 DOI: 10.3748/wjg.v19.i21.3199] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
208 Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134-e142. [PMID: 22239511 DOI: 10.1111/j.1365-2893.2011.01528.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 77] [Article Influence: 9.3] [Reference Citation Analysis]
209 Lu YF, Mauger DM, Goldstein DB, Urban TJ, Weeks KM, Bradrick SS. IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci Rep. 2015;5:16037. [PMID: 26531896 DOI: 10.1038/srep16037] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
210 Macaluso FS, Maida M, Minissale MG, Li Vigni T, Attardo S, Orlando E, Petta S. Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int. 2013;2013:564645. [PMID: 23956991 DOI: 10.1155/2013/564645] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
211 Romero-Gómez M, Turnes J, Ampuero J, Oyagüez I, Cuenca B, Gonzalez-Garcia J, Muñoz-Molina B, Aguilar R, Leal S, Planas R, Garcia-Samaniego J, Diago M, Crespo J, Calleja JL, Casado MA, Sola R. Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study. PLoS One 2015;10:e0122613. [PMID: 25826755 DOI: 10.1371/journal.pone.0122613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
212 de Kanter CT, Drenth JP, Arends JE, Reesink HW, van der Valk M, de Knegt RJ, Burger DM. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2014;53:409-27. [PMID: 24723109 DOI: 10.1007/s40262-014-0142-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
213 Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon 2012;12:e6151. [PMID: 23087759 DOI: 10.5812/hepatmon.6151] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
214 Poordad F, Chee GM. Interferon free hepatitis C treatment regimens: the beginning of another era. Curr Gastroenterol Rep 2012;14:74-7. [PMID: 22105465 DOI: 10.1007/s11894-011-0229-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
215 Oze T, Hiramatsu N, Song C, Yakushijin T, Iio S, Doi Y, Oshita M, Hagiwara H, Mita E, Ito T. Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin. J Gastroenterol. 2012;47:334-342. [PMID: 22109353 DOI: 10.1007/s00535-011-0498-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
216 Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf 2011;2:113-28. [PMID: 25083207 DOI: 10.1177/2042098611406318] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
217 Carvalho-Filho RJ, Dalgard O. Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin. Pharmgenomics Pers Med 2010;3:1-13. [PMID: 23226039 DOI: 10.2147/pgpm.s4461] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
218 Berenguer J, Calleja JL, Montes ML, Gil Á, Moreno A, Bañares R, Aldámiz-Echevarría T, Albillos A, Téllez MJ, Olveira A, Domínguez L, Fernández I, García-Samaniego J, Polo BA, Álvarez B, Ryan P, Barrio J, Devesa MJ, Benítez L, Santos I, Buey LG, Sanz J, Poves E, Losa JE, Fernández-Rodríguez C, Jarrín I, Calvo MJ, González-García J. HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1. Open Forum Infect Dis 2019;6:ofz214. [PMID: 31139679 DOI: 10.1093/ofid/ofz214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
219 Chung RT, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Di Bisceglie AM. Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology 2010;52:1906-14. [PMID: 21064034 DOI: 10.1002/hep.23947] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
220 Fujino T, Nakamuta M, Aoyagi Y, Kohjima M, Satoh T, Fukuda M, Ishibashi H, Yatsuhashi H, Enjoji M. Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin. Med Sci Monit 2011;17:CR687-91. [PMID: 22129899 DOI: 10.12659/msm.882127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
221 Friborg J, Levine S, Chen C, Sheaffer AK, Chaniewski S, Voss S, Lemm JA, McPhee F. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob Agents Chemother. 2013;57:1312-1322. [PMID: 23274666 DOI: 10.1128/aac.02239-12] [Cited by in Crossref: 43] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
222 Feld JJ, Bernstein DE, Younes Z, Vlierberghe HV, Larsen L, Tatsch F, Ferenci P. Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. Liver Int 2018;38:1571-5. [PMID: 29377566 DOI: 10.1111/liv.13708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
223 Vo KP, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, Wantuck J, Roytman MM, Tsai N, Cheung R, Li J, Nguyen MH. Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Dig Dis Sci 2015;60:1045-51. [DOI: 10.1007/s10620-015-3621-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
224 Venegas M, Villanueva RA, González K, Brahm J. IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients. World J Gastroenterol 2011; 17(31): 3636-3639 [PMID: 21987611 DOI: 10.3748/wjg.v17.i31.3636] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
225 Stanifer ML, Guo C, Doldan P, Boulant S. Importance of Type I and III Interferons at Respiratory and Intestinal Barrier Surfaces. Front Immunol 2020;11:608645. [PMID: 33362795 DOI: 10.3389/fimmu.2020.608645] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
226 Saludes V, Bracho MA, Valero O, Ardèvol M, Planas R, González-Candelas F, Ausina V, Martró E. Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors. PLoS One 2010;5:e14132. [PMID: 21152430 DOI: 10.1371/journal.pone.0014132] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
227 Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261 [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Reference Citation Analysis]
228 Jin YJ, Lee JW, Lee JI, Park SH, Park CK, Kim YS, Jeong SH, Kim YS, Kim JH, Hwang SG, Rim KS, Yim HJ, Cheong JY, Cho SW, Lee JS, Park YM, Jang JW, Lee CK, Sohn JH, Yang JM, Han S. Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population. BMC Gastroenterol 2013;13:74. [PMID: 23627926 DOI: 10.1186/1471-230X-13-74] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
229 Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H. Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients. Gastroenterol Res Pract. 2014;2014:549709. [PMID: 25197269 DOI: 10.1155/2014/549709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
230 Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM. 2013;106:153-163. [PMID: 23159839 DOI: 10.1093/qjmed/hcs214] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
231 Yang SS, Kao JH. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. Hepatol Int 2016;10:258-66. [PMID: 26542068 DOI: 10.1007/s12072-015-9668-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
232 Tovey MG, Lallemand C. Safety, Tolerability, and Immunogenicity of Interferons. Pharmaceuticals (Basel) 2010;3:1162-86. [PMID: 27713294 DOI: 10.3390/ph3041162] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
233 Tovo CV, Mattos AA, Almeida PRL. Chronic hepatitis C genotype 1 virus: Who should wait for treatment? World J Gastroenterol 2014; 20(11): 2867-2875 [PMID: 24659878 DOI: 10.3748/wjg.v20.i11.2867] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
234 Chen CH, Yu ML. Evolution of interferon-based therapy for chronic hepatitis C. Hepat Res Treat. 2010;2010:140953. [PMID: 21152178 DOI: 10.1155/2010/140953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
235 Dogan UB, Akin MS, Yalaki S. A low serum γ-glutamyltransferase level predicts a sustained virological response in patients with chronic hepatitis C genotype 1. Gut Liver. 2014;8:113-115. [PMID: 24516710 DOI: 10.5009/gnl.2014.8.1.113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
236 Petrovic J, Salkic N, Piljic D, Ahmetagic S, Jahic R, Porobic H, Smriko-Nuhanovic A, Hasanovic M. Clinical Characteristics and Treatment Efficasy of Chronic HCV Infection Among Intravenous Drug Users in Tuzla Canton. Mater Sociomed 2018;30:276-81. [PMID: 30936792 DOI: 10.5455/msm.2018.30.276-281] [Reference Citation Analysis]
237 O'Connor KS, Read SA, Wang M, Schibeci S, Eslam M, Ong A, Weltman MD, Douglas MW, Mazzola A, Craxì A, Petta S, Stewart GJ, Liddle C, George J, Ahlenstiel G, Booth DR. IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes Immun 2016;17:328-34. [PMID: 27307212 DOI: 10.1038/gene.2016.27] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
238 Wu LS, Jimmerson LC, MacBrayne CE, Kiser JJ, D'Argenio DZ. Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus. CPT Pharmacometrics Syst Pharmacol 2016;5:65-73. [PMID: 26933517 DOI: 10.1002/psp4.12058] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
239 Grasso A, Malfatti F, Testa R. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? World J Gastroenterol 2013; 19(41): 6947-6956 [PMID: 24222938 DOI: 10.3748/wjg.v19.i41.6947] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
240 Bota S, Sporea I, Şirli R, Popescu A, Neghină AM, Dănilă M, Străin M. Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review. World J Hepatol 2013; 5(3): 120-126 [PMID: 23556044 DOI: 10.4254/wjh.v5.i3.120] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
241 Liu Y, Li J, Gu Y, Ma L, Cen S, Peng Z, Hu L. Synthesis and structure-activity relationship study of new biaryl amide derivatives and their inhibitory effects against hepatitis C virus. Eur J Med Chem 2022;228:114033. [PMID: 34883293 DOI: 10.1016/j.ejmech.2021.114033] [Reference Citation Analysis]
242 Chatterjee A, Smith PF, Perelson AS. Hepatitis C viral kinetics: the past, present, and future. Clin Liver Dis. 2013;17:13-26. [PMID: 23177280 DOI: 10.1016/j.cld.2012.09.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
243 Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E. Simeprevir for the treatment of hepatitis C virus infection. Pharmgenomics Pers Med 2014;7:241-9. [PMID: 25206310 DOI: 10.2147/PGPM.S52715] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
244 Karayiannis P. Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) 2012;2012:478631. [PMID: 24278700 DOI: 10.6064/2012/478631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
245 Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses. 2013;5:1292-1324. [PMID: 23698400 DOI: 10.3390/v5051292] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 10.3] [Reference Citation Analysis]
246 Youngberg S, Brandt E, Barve A, Machineni S, Jones CT, Dabovic K, Jones CL, Colvin RA. A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers. J Drug Assess 2018;7:66-74. [PMID: 30370176 DOI: 10.1080/21556660.2018.1535438] [Reference Citation Analysis]
247 Sato I, Shimbo T, Kawasaki Y, Masaki N. Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database. Drug Des Devel Ther 2015;9:283-90. [PMID: 25565777 DOI: 10.2147/DDDT.S72245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
248 Lu NT, Crespi CM, Liu NM, Vu JQ, Ahmadieh Y, Wu S, Lin S, McClune A, Durazo F, Saab S, Han S, Neiman DC, Beaven S, French SW. A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. Phytother Res 2016;30:160-8. [PMID: 26621580 DOI: 10.1002/ptr.5518] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
249 Wu LS, Wang H, Geng XP. Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis. Exp Ther Med 2012;3:200-6. [PMID: 22969869 DOI: 10.3892/etm.2011.385] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
250 Pham TM, Tran SC, Lim YS, Hwang SB. Hepatitis C Virus-Induced Rab32 Aggregation and Its Implications for Virion Assembly. J Virol 2017;91:e01662-16. [PMID: 27852857 DOI: 10.1128/JVI.01662-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
251 Kumar A, Rajput MK, Paliwal D, Yadav A, Chhabra R, Singh S. Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries. Indian J Med Res 2018;147:445-55. [PMID: 30082568 DOI: 10.4103/ijmr.IJMR_1850_16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
252 Cipriano LE, Zaric GS, Holodniy M, Bendavid E, Owens DK, Brandeau ML. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One 2012;7:e45176. [PMID: 23028828 DOI: 10.1371/journal.pone.0045176] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
253 McPhee F, Friborg J, Levine S, Chen C, Falk P, Yu F, Hernandez D, Lee MS, Chaniewski S, Sheaffer AK, Pasquinelli C. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother. 2012;56:3670-3681. [PMID: 22508297 DOI: 10.1128/aac.00308-12] [Cited by in Crossref: 85] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
254 Frankova S, Jirsa M, Merta D, Neroldova M, Urbanek P, Senkerikova R, Spicak J, Sperl J. USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study. Ther Clin Risk Manag 2015;11:1853-61. [PMID: 26719699 DOI: 10.2147/TCRM.S94010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
255 Lin HH, Hsu SJ, Lu SN, Chuang WL, Hsu CW, Chien RN, Yang SS, Su WW, Wu JC, Lee TH, Peng CY, Tseng KC, Qin A, Huang YW, Chen PJ. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. JGH Open 2021;5:929-40. [PMID: 34386602 DOI: 10.1002/jgh3.12613] [Reference Citation Analysis]
256 Stahmeyer JT, Rossol S, Liersch S, Guerra I, Krauth C. Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany. PLoS One 2017;12:e0169401. [PMID: 28046099 DOI: 10.1371/journal.pone.0169401] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
257 Bourlière M, Pietri O, Castellani P, Oules V, Adhoute X. Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? Therap Adv Gastroenterol 2018;11:1756284818812358. [PMID: 30574189 DOI: 10.1177/1756284818812358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
258 Domagalski K, Pawłowska M, Tretyn A, Halota W, Pilarczyk M, Smukalska E, Linkowska K, Grzybowski T. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. Eur J Clin Microbiol Infect Dis 2013;32:745-54. [PMID: 23314745 DOI: 10.1007/s10096-012-1799-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
259 Martin-santos R, Egmond E, Cavero M, Mariño Z, Subira S, Navines R, Forns X, Valdes M. Chronic hepatitis C, depression and gender: a state of art. Advances in Dual Diagnosis 2015;8:193-210. [DOI: 10.1108/add-05-2015-0009] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
260 Boglione L, Pinna SM, Cardellino CS, De Nicolò A, Cusato J, Carcieri C, Cariti G, Di Perri G, D'Avolio A. Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. Infection 2017;45:103-6. [PMID: 27854063 DOI: 10.1007/s15010-016-0962-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
261 Odolini S, Amadasi S, Cerini C, Giralda M, Nasta P, Castelli F. Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV. BMC Infect Dis 2014;14 Suppl 5:S4. [PMID: 25236496 DOI: 10.1186/1471-2334-14-S5-S4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
262 Jothimani D, Chandy GM, Conjeevaram H. A new era in the treatment of chronic hepatitis C infection. Indian J Gastroenterol 2013;32:71-9. [PMID: 23054947 DOI: 10.1007/s12664-012-0254-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
263 Kłujszo E, Parcheta P, Zarębska-Michaluk D, Ochwanowska E, Witkowska A, Rakowska A, Rudnicka L, Kryczka W. Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C. J Dermatol Case Rep 2014;8:95-102. [PMID: 25621089 DOI: 10.3315/jdcr.2014.1183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
264 Alghamdi AS, Sanai FM, Ismail M, Alghamdi H, Alswat K, Alqutub A, Altraif I, Shah H, Alfaleh FZ; Saudi Association for the Study of Liver Diseases and Transplantation. SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol 2012;18 Suppl:S1-32. [PMID: 23006491 DOI: 10.4103/1319-3767.101155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
265 Meyer DF, Tobias H, Min AD, Rajendra A, Zic I, Brettholz E, Clain DJ, Klion F, Bernstein D, Bodenheimer HC. Retreatment of patients nonresponsive to pegylated interferon and ribavirin with daily high-dose consensus interferon. Hepat Res Treat 2010;2010:537827. [PMID: 21188197 DOI: 10.1155/2010/537827] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
266 Iadonato SP, Katze MG. Genomics: Hepatitis C virus gets personal. Nature. 2009;461:357-358. [PMID: 19759611 DOI: 10.1038/461357a] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
267 Alsiö Å, Rembeck K, Askarieh G, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Haagmans BL, Nasic S, Westin J, Hellstrand K, Norkrans G, Lagging M. Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. PLoS One 2012;7:e37521. [PMID: 22655053 DOI: 10.1371/journal.pone.0037521] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
268 Durante-Mangoni E, Parrella A, Iossa D, Andini R, Molaro R, Battimelli C, Sodano G, Utili R. Differential antiviral effects of pegylated interferon-α2a and pegylated interferon-α2b in chronic hepatitis C. Clin Drug Investig 2014;34:871-8. [PMID: 25349040 DOI: 10.1007/s40261-014-0241-y] [Reference Citation Analysis]
269 Linas BP, Barter DM, Leff JA, DiLorenzo M, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Freedberg KA. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS 2014;28:365-76. [PMID: 24670522 DOI: 10.1097/QAD.0000000000000093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
270 Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011;60:1284-93. [PMID: 21303914 DOI: 10.1136/gut.2010.222976] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 6.9] [Reference Citation Analysis]
271 Linas BP, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY. Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. Open Forum Infect Dis 2017;4:ofw266. [PMID: 28480259 DOI: 10.1093/ofid/ofw266] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
272 Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014;9:2051-67. [PMID: 24812506 DOI: 10.2147/IJN.S41822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
273 Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; the InC3 Study Group. Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC(3) study. J Viral Hepat. 2015;22:708-717. [PMID: 25580520 DOI: 10.1111/jvh.12384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
274 Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology. 2011;53:389-395. [PMID: 21274861 DOI: 10.1002/hep.24068] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
275 Marzio DLHD, Fenkel JM. Complementary and alternative medications in hepatitis C infection. World J Hepatol 2014; 6(1): 9-16 [PMID: 24653790 DOI: 10.4254/wjh.v6.i1.9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
276 Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ 2018;190:E677-87. [PMID: 29866893 DOI: 10.1503/cmaj.170453] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
277 Tong Y, Chi X, Yang W, Zhong J. Functional Analysis of Hepatitis C Virus (HCV) Envelope Protein E1 Using a trans-Complementation System Reveals a Dual Role of a Putative Fusion Peptide of E1 in both HCV Entry and Morphogenesis. J Virol 2017;91:e02468-16. [PMID: 28100619 DOI: 10.1128/JVI.02468-16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
278 Miao M, Jing X, De Clercq E, Li G. Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy. Drug Des Devel Ther 2020;14:2759-74. [PMID: 32764876 DOI: 10.2147/DDDT.S254754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
279 Morio R, Imamura M, Kawakami Y, Morio K, Kobayashi T, Yokoyama S, Kimura Y, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Nelson Hayes C, Aikata H, Takahashi S, Miki D, Ochi H, Mori N, Takaki S, Tsuji K, Chayama K. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. J Gastroenterol 2017;52:504-11. [DOI: 10.1007/s00535-016-1255-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
280 Pouryasin M, Keshvari M, Sharafi H, Alavian SM, Behnava B, Alavian SE, Pouryasin A. The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C. Hepat Mon 2016;16:e35278. [PMID: 27148387 DOI: 10.5812/hepatmon.35278] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
281 Liu CH, Huang CF, Liu CJ, Dai CY, Huang JF, Lin JW, Liang CC, Yang SS, Lin CL, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Kao JH, Yu ML. Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. Sci Rep 2015;5:15255. [PMID: 26469083 DOI: 10.1038/srep15255] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
282 Pellicelli AM, Romano M, Stroffolini T, Mazzoni E, Mecenate F, Monarca R, Picardi A, Bonaventura ME, Mastropietro C, Vignally P, Andreoli A, Marignani M, D'Ambrosio C, Miglioresi L, Nosotti L, Mitidieri O, Gentilucci UV, Puoti C, Barbaro G, Barlattani A, Furlan C, Barbarini G; CLEO Group. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. BMC Gastroenterol 2012;12:162. [PMID: 23157720 DOI: 10.1186/1471-230X-12-162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
283 Melia MT, Bräu N, Poordad F, Lawitz EJ, Shiffman ML, McHutchison JG, Muir AJ, Galler GW, Nyberg LM, Lee WM, Schiff E, Long J, Noviello S, Brass CA, Pedicone LD, Sulkowski MS. Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study. Clin Infect Dis 2014;58:960-9. [PMID: 24399086 DOI: 10.1093/cid/ciu009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
284 Rivero-Juárez A, Lopez-Cortes LF, Camacho A, Torres-Cornejo A, Pineda JA, Marquez-Solero M, Caruz A, Ruiz-Valderas R, Torre-Cisneros J, Gutierrez-Valencia A, Rivero A. Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients. PLoS One 2012;7:e48959. [PMID: 23145040 DOI: 10.1371/journal.pone.0048959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
285 Juneja M, Euliano R, Satoskar R, Lewis JH. Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis. Dig Dis Sci 2013;58:3348-58. [PMID: 23925819 DOI: 10.1007/s10620-013-2812-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
286 Badiger R, Mitchell JA, Gashaw H, Galloway-Phillipps NA, Foser S, Tatsch F, Singer T, Hansel TT, Manigold T. Effect of different interferonα2 preparations on IP10 and ET-1 release from human lung cells. PLoS One 2012;7:e46779. [PMID: 23056449 DOI: 10.1371/journal.pone.0046779] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
287 Pouresmaeeli M, Alavian SM, Keshvari M, Salimi S, Mehrnoush L. Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C. Hepat Mon 2015;15:e30780. [PMID: 26504470 DOI: 10.5812/hepatmon.30780] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
288 Tsubota A, Fujise K, Namiki Y, Tada N. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol 2011; 17(4): 419-432 [PMID: 21274371 DOI: 10.3748/wjg.v17.i4.419] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
289 Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol. 2012;30:1117-1124. [PMID: 23138311 DOI: 10.1038/nbt.2424] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 7.8] [Reference Citation Analysis]
290 Sweiti H, Ekwunife O, Jaschinski T, Lhachimi SK. Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review. Curr Ther Res Clin Exp 2017;84:10-21. [PMID: 28761574 DOI: 10.1016/j.curtheres.2017.01.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
291 Ansari MA, Pedergnana V, L C Ip C, Magri A, Von Delft A, Bonsall D, Chaturvedi N, Bartha I, Smith D, Nicholson G, McVean G, Trebes A, Piazza P, Fellay J, Cooke G, Foster GR, Hudson E, McLauchlan J, Simmonds P, Bowden R, Klenerman P, Barnes E, Spencer CCA; STOP-HCV Consortium. Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat Genet 2017;49:666-73. [PMID: 28394351 DOI: 10.1038/ng.3835] [Cited by in Crossref: 79] [Cited by in F6Publishing: 60] [Article Influence: 15.8] [Reference Citation Analysis]
292 Chang CC, Crane M, Zhou J, Mina M, Post JJ, Cameron BA, Lloyd AR, Jaworowski A, French MA, Lewin SR. HIV and co-infections. Immunol Rev 2013;254:114-42. [PMID: 23772618 DOI: 10.1111/imr.12063] [Cited by in Crossref: 75] [Cited by in F6Publishing: 61] [Article Influence: 9.4] [Reference Citation Analysis]
293 Kurelac I, Papic N, Sakoman S, Orban M, Dusek D, Coric M, Vince A. Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate: experience From Croatian Reference Center for Viral Hepatitis. Hepat Mon 2011;11:986-92. [PMID: 22368683 DOI: 10.5812/kowsar.1735143x.4216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
294 Hesamizadeh K, Tavakoli A, Nikbin M. Peg-interferon Plus Ribavirin Combination Therapy in HCV Mono-infected and HCV/HIV Co-infected Patients in Iran. Med J Islam Repub Iran 2019;33:63. [PMID: 31456987 DOI: 10.34171/mjiri.33.63] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
295 Backus LI, Belperio PS. Effectiveness research in the evolving HCV landscape. Dig Dis Sci 2014;59:2845-7. [PMID: 25190262 DOI: 10.1007/s10620-014-3345-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
296 Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health 2011;101:2151-5. [PMID: 21940910 DOI: 10.2105/AJPH.2011.300251] [Cited by in Crossref: 56] [Cited by in F6Publishing: 29] [Article Influence: 5.1] [Reference Citation Analysis]
297 Crosignani A, Riva A, Della Bella S. Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World J Gastroenterol 2016; 22(4): 1393-1404 [PMID: 26819508 DOI: 10.3748/wjg.v22.i4.1393] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
298 Zaily DG, Marlen CF, Santiago DC, Gillian MD, Carmen VS, Zurina CE, Enrique R AS, Liz AL, Lisset GF, Sacha LDV, Elena FB. Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C. Curr Ther Res Clin Exp 2017;85:20-8. [PMID: 29158855 DOI: 10.1016/j.curtheres.2017.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
299 Jazwinski AB, Muir AJ. Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. Gastroenterol Clin North Am 2011;40:481-94. [PMID: 21893269 DOI: 10.1016/j.gtc.2011.06.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
300 Zhao H, Lin W, Kumthip K, Cheng D, Fusco DN, Hofmann O, Jilg N, Tai AW, Goto K, Zhang L. A functional genomic screen reveals novel host genes that mediate interferon-alpha’s effects against hepatitis C virus. J Hepatol. 2012;56:326-333. [PMID: 21888876 DOI: 10.1016/j.jhep.2011.07.026] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
301 Kurelac I, Papic N, Sakoman S, Orban M, Dusek D, Coric M, Vince A. Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate: experience From Croatian Reference Center for Viral Hepatitis. Hepat Mon. 2011;11:986-992. [PMID: 22368683 DOI: 10.5812/kowsar.1735143X.779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
302 García-García I, González-Delgado CA, Valenzuela-Silva CM, Díaz-Machado A, Cruz-Díaz M, Nodarse-Cuní H, Pérez-Pérez O, Bermúdez-Badell CH, Ferrero-Bibilonia J, Páez-Meireles R, Bello-Rivero I, Castro-Odio FR, López-Saura PA; FarmaPEG Study Group. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. BMC Pharmacol 2010;10:15. [PMID: 21092287 DOI: 10.1186/1471-2210-10-15] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
303 Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, Daurès JP, Blanc P. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis. Drugs. 2013;73:263-277. [PMID: 23436591 DOI: 10.1007/s40265-013-0027-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
304 Ascione A. Boceprevir in chronic hepatitis C infection: a perspective review. Ther Adv Chronic Dis. 2012;3:113-121. [PMID: 23251772 DOI: 10.1177/2040622312441496] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
305 Choi JW, Lee JS, Paik WH, Song TJ, Kim JW, Bae WK, Kim KA, Kim JG. Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C. Clin Mol Hepatol 2016;22:168-71. [PMID: 27044768 DOI: 10.3350/cmh.2016.22.1.168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
306 Allen AM, Kim WR, Larson J, Loftus EV Jr. Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:1655-60.e1. [PMID: 23891915 DOI: 10.1016/j.cgh.2013.07.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
307 Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;348:g3308. [PMID: 25002352 DOI: 10.1136/bmj.g3308] [Cited by in Crossref: 142] [Cited by in F6Publishing: 135] [Article Influence: 17.8] [Reference Citation Analysis]